Results 321 to 330 of about 66,239 (358)

Rivaroxaban Is Associated With Higher Rates of Gastrointestinal Bleeding Than Other Direct Oral Anticoagulants

Annals of Internal Medicine, 2021
BACKGROUND Gastrointestinal bleeding (GIB) rates for direct oral anticoagulants (DOACs) and warfarin have been extensively compared. However, population-based studies comparing GIB rates among different DOACs are limited.
A. B. Ingason, J. Hreinsson, A. Agustsson, S. Lund, Edward Rumba, Daníel A. Pálsson, I. E. Reynisson, Brynja R Guðmundsdóttir, P. Önundarson, E. Björnsson   +9 more
semanticscholar   +1 more source

Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data

Annals of Internal Medicine, 2021
BACKGROUND Apixaban and rivaroxaban are replacing vitamin K antagonists for the treatment of venous thromboembolism (VTE) in adults; however, head-to-head comparisons remain limited. OBJECTIVE To assess the effectiveness and safety of apixaban compared
G. Dawwas, Charles E. Leonard, J. Lewis, A. Cuker   +3 more
semanticscholar   +1 more source

Use of rivaroxaban in patients with stroke

Neurological Sciences, 2017
Rivaroxaban, an inhibitor of Factor Xa, is a direct oral anti-coagulant that has been found to be non-inferior to warfarin in preventing cerebral ischemia in patients with non-valvular atrial fibrillation and in the subgroup of patients with a history of the previous stroke or transient ischemic attack.
Toni, Danilo, Carolei, Antonio, Caso, Valeria, Consoli, Domenico, Del Sette, Massimo, Inzitari, Domenico, Melis, Maurizio, Micieli, Giuseppe, Provinciali, Leandro, Ricci, Stefano, Santalucia, Paola, Toso, Vito   +11 more
openaire   +4 more sources

Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation.

New England Journal of Medicine
BACKGROUND Abelacimab is a fully human monoclonal antibody that binds to the inactive form of factor XI and blocks its activation. The safety of abelacimab as compared with a direct oral anticoagulant in patients with atrial fibrillation is unknown ...
Christian T. Ruff, Siddharth M. Patel, R. Giugliano, David A. Morrow, Bruce Hug, J. Kuder, Erica L Goodrich, Shih-Ann Chen, Shaun G Goodman, Boyoung Joung, Robert G Kiss, Jindrich Spinar, Wojciech Wojakowski, Jeffrey I Weitz, S. Murphy, S. Wiviott, Sanobar Parkar, Dan Bloomfield, M. Sabatine   +18 more
semanticscholar   +1 more source

Effects of Rivaroxaban on Platelet Aggregation

Journal of Cardiovascular Pharmacology, 2020
Abstract: Rivaroxaban is a direct oral anti-factor Xa anticoagulant. It has recently been suggested that rivaroxaban may affect platelet function in vitro; however, little is known about the clinical impact of this likely antiplatelet effect and whether this probable phenomenon is dose-dependent.
Hugo Guillermo Espejo-Godinez, Abraham Majluf-Cruz, Jose Rubicel Hernandez-Lopez, Irma Isordia-Salas, Jesús Hernández-Juárez, Karim Majluf-Cruz, Jose Antonio Alvarado Moreno, Rodrigo Mancilla-Padilla, Manuel Moreno-Hernández   +8 more
openaire   +3 more sources

Developing Deep Venous Thrombosis while on Rivaroxaban: A Review of Rivaroxaban

Clinical Case Reports, 2020
Rivaroxaban is a Direct Oral Anticoagulant (DOAC), which has six licensed indications, including the use for prevention of stroke and systemic embolism with non-valvular Atrial Fibrillation (AF) and the treatment of Venous Thromboembolism (VTE). The pharmacokinetics and the pharmacogenetics of rivaroxaban are reviewed by the author because of a ...
openaire   +2 more sources

Rivaroxaban : mode d’action

Annales Françaises d'Anesthésie et de Réanimation, 2008
Rivaroxaban is the first oral anticoagulant with a direct anti-Xa activity to be registered (approval). As for all first comers in a class, it should be assessed both for itself and for the class. The targeting of factor-Xa factor, key component in the coagulation cascade, has the theoretical benefit of being an effective antithrombotic and a potential
openaire   +3 more sources

An Improved Synthesis of Rivaroxaban

Organic Preparations and Procedures International, 2017
Rivaroxaban (1) is a novel, oral, selective direct inhibitor of factor Xa developed by Bayer Healthcare.1,2 It has been approved by the EMEA and FDA for the prevention of venous thromboembolism in ...
Chen Bo, Bo Tang, Shaixiao Tian, Gao Qingjiao, Zhang Qinghua, Xu Guangyu, Minzhong Zhang   +6 more
openaire   +2 more sources

Rash associated with rivaroxaban use

American Journal of Health-System Pharmacy, 2018
A case of a patient who developed a hypersensitivity reaction to rivaroxaban in the form of a diffuse, exanthematous rash is reported.After starting rivaroxaban for treatment of cancer-associated deep vein thrombosis (DVT) with pulmonary embolism (PE), a 69-year-old Caucasian woman arrived at an oncology clinic with a diffuse, exanthematous ...
Kelly M. Rudd, Anush Patel, Narmadha Panneerselvam   +2 more
openaire   +2 more sources

Rivaroxaban: a novel anticoagulant

British Journal of Cardiac Nursing, 2013
Rivaroxaban is an oral anticoagulant licensed for the treatment of acute deep vein thrombosis (DVT), and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT in adults. It is also licensed for the prevention of stroke and systemic embolism in adult patients with additional risk factors with non-valvular atrial fibrillation ...
Helen Williams, Margaret Haalstrup
openaire   +2 more sources